Isomorphic Labs's banner

Isomorphic Labs

@IsomorphicLabs • 65,908 subscribers

Solve all disease. Developing and applying frontier AI to unlock deeper scientific insights, faster breakthroughs, and life-changing medicines.

Shorts

Previously, 85% of proteins associated with human disease were deemed intractable – their shapes and function made them less suitable for traditional chemical screening in the lab. Moving from experimental screening to AI generative design on a computer, we have seen these targets drastically open up the potential to design molecules with atomic precision, fundamentally expanding the number of diseases we can treat.

Previously, 85% of proteins associated with human disease were deemed intractable – their shapes and function made them less suitable for traditional chemical screening in the lab. Moving from experimental screening to AI generative design on a computer, we have seen these targets drastically open up the potential to design molecules with atomic precision, fundamentally expanding the number of diseases we can treat.

37,529 Aufrufe

We're excited to announce #AlphaFold 3 with Google DeepMind in nature: our new AI model for predicting biomolecule structures with unprecedented breadth and accuracy. Expanding beyond proteins to tackle DNA, RNA, small molecules to fuel advances in biology & drug design 🧵

We're excited to announce #AlphaFold 3 with Google DeepMind in nature: our new AI model for predicting biomolecule structures with unprecedented breadth and accuracy. Expanding beyond proteins to tackle DNA, RNA, small molecules to fuel advances in biology & drug design 🧵

297,444 Aufrufe

The prediction: 5 years for the industry to realise AI is essential in drug design and development – Max Jaderberg. While this episode aired a year ago, we’ve been building for almost 5 years already, and have always held the conviction that our AI will redefine how new medicines are made.

The prediction: 5 years for the industry to realise AI is essential in drug design and development – Max Jaderberg. While this episode aired a year ago, we’ve been building for almost 5 years already, and have always held the conviction that our AI will redefine how new medicines are made.

21,598 Aufrufe

"At ICML, Agnieszka Podsiadło and I are sharing some of what we're building at Isomorphic Labs: Methods that can generalise drug discovery - finding new biology, at scale and across pretty much every therapeutic modality. That last part matters to me most - it's how you get to a place where no patient is left behind." - Andreas Loukas, AI research scientist. If you're in Seoul this week, come say hi to Andreas - Andreas Loukas and the rest of our delegation at ICML.

"At ICML, Agnieszka Podsiadło and I are sharing some of what we're building at Isomorphic Labs: Methods that can generalise drug discovery - finding new biology, at scale and across pretty much every therapeutic modality. That last part matters to me most - it's how you get to a place where no patient is left behind." - Andreas Loukas, AI research scientist. If you're in Seoul this week, come say hi to Andreas - Andreas Loukas and the rest of our delegation at ICML.

17,764 Aufrufe

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:

Isomorphic Labs

310,089 Aufrufe • vor 6 Monaten

From small molecules to complex biologics, the universe of potential medicines spanning multiple modalities is astronomically vast. To put it in perspective: conservative estimates place the vast chemical search space for small, drug-like molecules near 10^60. The observable universe contains fewer stars – somewhere between 10^22 and 10^24. The answers to drug discovery’s toughest challenges exist within this vast space. And now, our drug design engine (IsoDDE) gives us the capability to navigate it.

From small molecules to complex biologics, the universe of potential medicines spanning multiple modalities is astronomically vast. To put it in perspective: conservative estimates place the vast chemical search space for small, drug-like molecules near 10^60. The observable universe contains fewer stars – somewhere between 10^22 and 10^24. The answers to drug discovery’s toughest challenges exist within this vast space. And now, our drug design engine (IsoDDE) gives us the capability to navigate it.

Isomorphic Labs

71,150 Aufrufe • vor 1 Monat

We recently released a technical report highlighting how Isomorphic Labs’ drug design engine is achieving a step change in how we model complex biological mechanisms, consistently outperforming industry benchmarks. Read our blog to discover how we’re bridging the gap between structure prediction and rational drug design. You can find the link in the comments.

We recently released a technical report highlighting how Isomorphic Labs’ drug design engine is achieving a step change in how we model complex biological mechanisms, consistently outperforming industry benchmarks. Read our blog to discover how we’re bridging the gap between structure prediction and rational drug design. You can find the link in the comments.

Isomorphic Labs

125,621 Aufrufe • vor 8 Monaten

Over the last 50 years, computer-aided design has revolutionised almost every major engineering field – but its revolution in making medicines has only just begun. Moving from manual execution to AI-driven design unlocks a depth and scale that was previously impossible. Our drug design engine, IsoDDE, intelligently searches vast chemical spaces to design functional molecules ready for the real world. What used to take months of lab work now happens computationally in just days. The visualisation below is a representation of our drug design agent working autonomously over a 2-4 day period. Starting with a strict design specification (the biological target and desired molecular properties), our AI agent autonomously searches and iteratively generates new molecule designs that result in real world functional progress.

Over the last 50 years, computer-aided design has revolutionised almost every major engineering field – but its revolution in making medicines has only just begun. Moving from manual execution to AI-driven design unlocks a depth and scale that was previously impossible. Our drug design engine, IsoDDE, intelligently searches vast chemical spaces to design functional molecules ready for the real world. What used to take months of lab work now happens computationally in just days. The visualisation below is a representation of our drug design agent working autonomously over a 2-4 day period. Starting with a strict design specification (the biological target and desired molecular properties), our AI agent autonomously searches and iteratively generates new molecule designs that result in real world functional progress.

Isomorphic Labs

15,240 Aufrufe • vor 1 Monat

Drug discovery is incredibly complex, but you don't need a background in biology to help solve it. Hear from software engineer, Bartosz Bacewisz, on how transferable skills in tech and a shared motivation are helping us build frontier AI models to reimagine medicine.

Drug discovery is incredibly complex, but you don't need a background in biology to help solve it. Hear from software engineer, Bartosz Bacewisz, on how transferable skills in tech and a shared motivation are helping us build frontier AI models to reimagine medicine.

Isomorphic Labs

15,457 Aufrufe • vor 2 Monaten

How could #AlphaFold 3 transform drug discovery? Most drugs are small molecules known as ligands that bind to proteins to change how they interact in human health and disease. AlphaFold 3 can predict these interactions to atomic accuracy.

How could #AlphaFold 3 transform drug discovery? Most drugs are small molecules known as ligands that bind to proteins to change how they interact in human health and disease. AlphaFold 3 can predict these interactions to atomic accuracy.

Isomorphic Labs

75,442 Aufrufe • vor 2 Jahren

Hear from John Strafford from Iso Business Development, on how combining Isomorphic Labs' capabilities with industry-leading partners sets us all up for success.

Hear from John Strafford from Iso Business Development, on how combining Isomorphic Labs' capabilities with industry-leading partners sets us all up for success.

Isomorphic Labs

10,957 Aufrufe • vor 2 Monaten

"If you are keen to learn new stuff, you can come here and learn the most important things about the domain itself, on the job…" Kuba Perlin, ML Staff Research Engineer, shares his insights into Iso's unique approach and explains why a formal science background isn't essential.

"If you are keen to learn new stuff, you can come here and learn the most important things about the domain itself, on the job…" Kuba Perlin, ML Staff Research Engineer, shares his insights into Iso's unique approach and explains why a formal science background isn't essential.

Isomorphic Labs

15,476 Aufrufe • vor 4 Monaten

“One of the great things about Iso is how interdisciplinary everyone is, people come from so many different backgrounds.” We spoke with Bilal Khan, Software Engineer at Isomorphic Labs, about our unique, collaborative culture and frontier AI built to tackle the world's most complex problems. Watch the video and head to the comments to explore our current roles.

“One of the great things about Iso is how interdisciplinary everyone is, people come from so many different backgrounds.” We spoke with Bilal Khan, Software Engineer at Isomorphic Labs, about our unique, collaborative culture and frontier AI built to tackle the world's most complex problems. Watch the video and head to the comments to explore our current roles.

Isomorphic Labs

19,870 Aufrufe • vor 8 Monaten

Check out 'Inside Iso', our new video series taking people inside Isomorphic Labs, and learn what keeps our 'Isos' intrigued as we work to change the way drug discovery is done. Join us! #AI #machinelearning #drugdiscovery

Check out 'Inside Iso', our new video series taking people inside Isomorphic Labs, and learn what keeps our 'Isos' intrigued as we work to change the way drug discovery is done. Join us! #AI #machinelearning #drugdiscovery

Isomorphic Labs

30,389 Aufrufe • vor 3 Jahren

ML Research Scientists @PeteWirnsberger and Daniele Grattarola discuss impactful ML research in application to drug design. If you’re attending #ICML2024 meet the team to hear how these techniques are applied at IsoLabs. Register your interest here:

ML Research Scientists @PeteWirnsberger and Daniele Grattarola discuss impactful ML research in application to drug design. If you’re attending #ICML2024 meet the team to hear how these techniques are applied at IsoLabs. Register your interest here:

Isomorphic Labs

10,193 Aufrufe • vor 2 Jahren

Keine weiteren Inhalte verfügbar